DoH, Sanofi partner to accelerate development of new global vaccines in Abu Dhabi

19 June 2025 16:08
BOSTON (WAM)The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has signed a Memorandum of Understanding (MoU) with Sanofi, a research and development-driven, AI-powered healthcare biopharma company at the BIO International Convention 2025, in Boston, USA.The collaboration will leverage the Emirate's health-tech ecosystem and advanced research infrastructure to drive the development of new global vaccines and strengthen regional capabilities in vaccine manufacturing.In the presence of Dr. Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi, and Laurie Gery, Global Head of Business Development, Vaccines at Sanofi, the agreement was signed during the BIO International Convention in Boston, USA, by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Baptiste de Clarens, General Manager Greater Gulf, Vaccines at Sanofi.Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the DoH, said. 'DoH is partnering with Sanofi to expedite the development of new global vaccines. This initiative aims to shorten the timeline from early research to public availability by utilising advanced technologies, real-time data analysis, and conducting parallel clinical trial phases. By combining Sanofi's global scientific expertise with Abu Dhabi's state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships. Abu Dhabi offers a globally connected, purpose-driven environment for leading research, and together we will drive a transformative change that will safeguard the health and well-being of our community while contributing to global health security.'Both entities will work together to streamline regulatory processes, enhance manufacturing preparedness, and promote knowledge sharing between local and international experts. This partnership reflects Abu Dhabi's strategic goal to establish itself as a leading centre for bio- and pharmaceutical innovation and underscores the emirate's commitment to advancing proactive, technology-driven healthcare solutions.Baptiste de Clarens, General Manager Greater Gulf, Vaccines, Sanofi, said, 'The Memorandum of Understanding signed with the Department of Health – Abu Dhabi marks an encouraging step towards advancing global health security while reflecting our shared interest in addressing global health challenges through scientific partnership. This agreement allows us to examine how Sanofi's experience in vaccine development could complement Abu Dhabi's growing R&D ecosystem. Through this initial framework, we look forward to exploring opportunities for public-private collaboration in healthcare innovation.'
In addition, both the Department and Sanofi will advance clinical research and development planning, optimise resource allocation and establish the foundational terms for funding and access. These efforts are designed to enhance healthcare resilience and sustainability across Abu Dhabi's healthcare sector and beyond, expanding access to quality care for patients locally and globally.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Filipino Times

35 minutes ago

• Filipino Times

Abu Dhabi launches personalized weight loss programme; first in the Middle East

Abu Dhabi has launched the region's first Personalised Weight Management Programme to help residents manage their weight and prevent serious health problems. The program aims to lower the risk of diseases like type 2 diabetes, heart problems, and some cancers, improving the quality of life and helping people live longer, Abu Dhabi Media Office reported. An initiative of the Department of Health – Abu Dhabi (DoH) and Abu Dhabi Public Health Centre (ADPHC), this is the first program of its kind in the Middle East that combines online health tracking, insurance support, and medical care tailored to each person. 'Our focus is on health – not just weight. This programme supports our vision for an active, health-conscious community, empowering individuals through personalised and science-driven solutions,' Dr. Noura Al Ghaithi, Undersecretary of DoH, said. Those eligible include Thiqa insurance members aged 18 and above who are medically classified as overweight or obese. The plan includes early health checks, one-on-one coaching, diet and exercise guidance, and check-ups using the Sahatna health app.

Al Etihad

12 hours ago

• Al Etihad

DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi

20 June 2025 22:37 BOSTON (WAM) Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership during the BIO International Convention in Boston agreement aims to localise the manufacturing of pharmaceuticals in Abu Dhabi and advance digital health Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said, 'Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences." She added, "By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community.'The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development his part, Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, said, 'Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi." Bachir added, "Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE.'Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 - 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the US, aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI).

Arabian Business

19 hours ago

• Arabian Business

DoH and Sanofi partner to develop new global vaccines in Abu Dhabi

The Department of Health – Abu Dhabi (DoH) and Sanofi, one of the world's leading biopharma companies, will team up to develop new global vaccines and strengthen regional capabilities in vaccine manufacturing. The two organisations signed a memorandum of understanding to this effect at the BIO International Convention 2025, in Boston, USA, recently. Dr Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi, and Laurie Gery, Global Head of Business Development, Vaccines at Sanofi, were present at the signing ceremony. DoH and Sanofi strengthen health collaboration The collaboration will leverage Abu Dhabi's health-tech ecosystem and advanced research infrastructure and Sanofi's research and development expertise. It reflects Abu Dhabi's goal to establish the emirate as a leading centre for bio- and pharmaceutical innovation. Both entities will collaborate to streamline regulatory processes, enhance manufacturing preparedness, and foster knowledge sharing among local and international experts. View this post on Instagram A post shared by دائرة الصحة – أبوظبي "DoH" (@dohsocial) Dr Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the DoH, commented: 'DoH is partnering with Sanofi to expedite the development of new global vaccines. This initiative aims to shorten the timeline from early research to public availability by utilising advanced technologies, real-time data analysis, and conducting parallel clinical trial phases. 'By combining Sanofi's global scientific expertise with Abu Dhabi's state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships. Abu Dhabi offers a globally connected, purpose-driven environment for leading research, and together we will drive a transformative change that will safeguard the health and well-being of our community while contributing to global health security.' Both organisations will advance clinical research and development planning, optimise resource allocation and establish the foundational terms for funding and access. DoH and Sanofi are collaborating in other areas as well. In 2022, the two parties agreed to work on four strategic healthcare priorities, including hematology and oncology, rare metabolic diseases, diabetes management and vaccines. Baptiste de Clarens, General Manager Greater Gulf, Vaccines, Sanofi, added: 'The Memorandum of Understanding signed with the Department of Health – Abu Dhabi marks an encouraging step towards advancing global health security while reflecting our shared interest in addressing global health challenges through scientific partnership. 'This agreement allows us to examine how Sanofi's experience in vaccine development could complement Abu Dhabi's growing R&D ecosystem. Through this initial framework, we look forward to exploring opportunities for public-private collaboration in healthcare innovation.'